Recall Register

Drug recall: Adbry, (tralokinumab-ldrm) injection, 300 mg/2mL, Packaged as a) 1 x Single dose Autoinjector, SAMPLE NOT FOR SALE…

Class II FDA enforcement event 98401. Recall start date: . Status in the FDA record: Ongoing.

Reason for recall, in the words of FDA

Lack of Assurance of Sterility: due to the presence of particulate matter in one unit from the lot, which lab tests have identified as wool fiber.

Class II, in the words of FDA

a situation in which use of or exposure to a violative product may cause temporary or medically reversible adverse health consequences or where the probability of serious adverse health consequences is remote

LEO PHARMA INC started this drug recall on 10 Feb 2026. The firm address in the FDA record is in Madison, NJ. FDA put the recall in Class II. FDA event 98401 has 1 product record. The first FDA enforcement report date is 4 Mar 2026. The record gives the status Ongoing.

It is important to note that most of the time recall classifications are determined after the recalling firm provides all of the information needed to determine the risk posed to public health. The classification and posting in the FDA Enforcement Report should not be seen as an expansion or change to a firm’s voluntary public warning.

FDA publishes these words. Source: FDA, Enforcement Reports, Important Note, read on . openFDA export of .

Distribution

In the words of FDA.

Nationwide in the USA

Recalling firm

LEO PHARMA INC, Madison, NJ.

Recalling firm: The firm that the FDA record names for a recall.

FDA records how the recall started: Voluntary: Firm initiated.

Products

1 product record in the event.

FDA event 98401: product records
Recall numberProductQuantityClassStatusReport date
D-0339-2026Adbry, (tralokinumab-ldrm) injection, 300 mg/2mL, Packaged as a) 1 x Single dose Autoinjector, SAMPLE NOT FOR SALE, NDC 50222-350-91; b) 2 x Single dose Autoinjectors, NDC 50222-350-02; Rx only, Manufactured by: LEO Pharma A/S. Industriparken 55, DK-2750 Ballerup, Denmark, Distributed by: LEO Pharma Inc., Madison, NJ…11,407 unitsClass IIOngoing4 Mar 2026

openFDA, about the status: FDA does not update the status of a recall after the recall has been classified according to its level of hazard. As such, the status of a recall (open, completed, or terminated) will remain unchanged after published in the Enforcement Reports. Source: openFDA, Drug Recall Enforcement Reports, Disclaimer.

Enforcement report: The FDA publication that lists recalls. It has one record for each product of a recall.

Enforcement event: All the product records that have one FDA event number. This site shows one event on one page.

Class II: The middle of the three FDA recall classes.

The event in context

Drug events that started in 2026
234
Share of these events in Class II
74%
Product records in this event
1Median of the firm: 1
Events of the firm on the register
3

Other events of the firm

Official channels

Cite this page

Recall Register. FDA enforcement event 98401. https://recallregister.com/fda/ii/98401/. Source: openFDA enforcement reports. Data through .

Sources

Source
openFDA drug enforcement reports
Licence
CC0 1.0
Export date
28 Sep 2026
Newest FDA report date on the register
23 Sep 2026

FDA has one record for each product. This site puts the records with the same event number on one page. The class of the event is the highest class of its records. How the register is made. Report an error.

Questions

Where was the product distributed?
The FDA record gives this distribution: Nationwide in the USA
What quantity of product is in FDA event 98401?
The FDA record gives this quantity: 11,407 units
How did the recall start?
The FDA record says: Voluntary: Firm initiated
How many drug recalls of 2026 have the same class?
74% of the 234 drug events that started in 2026 are in Class II.